Back to Search
Start Over
Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial
- Source :
- Journal of dental research, Journal of Dental Research, Vol. 95, No 3 (2016) pp. 349-355
- Publication Year :
- 2015
-
Abstract
- Accumulating evidence suggests that periodontal infections may have an impact on systemic health. In patients with untreated periodontitis, very high values for several inflammatory markers in serum are expressed simultaneously. We investigated to what extent these peak values change after nonsurgical and surgical periodontal treatment, with adjunctive antibiotics administered during the first or the second treatment phase. In a single-center, randomized, placebo-controlled, and double-masked clinical trial, 80 patients with chronic or aggressive periodontitis were randomized into 2 treatment groups: group A, receiving systemic amoxicillin and metronidazole during the first, nonsurgical phase of periodontal therapy (phase 1), and group B, receiving the antibiotics during the second, surgical phase (phase 2). Serum samples were obtained at baseline (BL), 3 mo after phase 1 (M3), and 6 and 12 mo after phase 2 (M6, M12). Samples were evaluated for 15 cytokines and 9 acute-phase proteins using the Bio-Plex bead array multianalyte detection system. For each analyte, peak values were defined as greater than mean +2 SD of measurements found in 40 periodontally healthy persons. Sixty-six patients showed a peak value of at least 1 analyte at BL. At M12, the number of these patients was only 36 ( P = 0.0002). This decrease was stronger in group A (BL: 35, M12: 19, P = 0.0009) than in group B (BL: 31, M12: 17, P = 0.14). Twenty patients displayed peak values of at least 4 biomarkers at BL. The nonsurgical therapy delivered in the first phase reduced most of these peaks (group A, BL: 9, M3: 4, P = 0.17; group B, BL: 11, M3: 2, P = 0.01), irrespective of adjunctive antibiotics. The reductions obtained at M3 were maintained until M12 in both groups. Initial, nonsurgical periodontal therapy reduced the incidence of peak levels of inflammatory markers. Antibiotics and further surgical therapy did not enhance the effect ( Clinicaltrials.gov NCT02197260).
- Subjects :
- Serum
Male
Antibiotics
Acute-Phase Proteins/analysis
Gastroenterology
Group B
law.invention
Clinical research
Placebos
0302 clinical medicine
Randomized controlled trial
Chronic Periodontitis/blood/drug therapy/surgery
law
Aggressive periodontitis
030212 general & internal medicine
Amoxicillin/therapeutic use
Interleukin-10/blood
Antimicrobials
Middle Aged
Calcitonin/blood
Combined Modality Therapy
3. Good health
Anti-Bacterial Agents
Interleukin-10
Serum Amyloid P-Component
Aggressive Periodontitis
Inflammation Mediators/blood
Cytokines
Female
Inflammation Mediators
medicine.drug
Adult
Calcitonin
medicine.medical_specialty
Periodontal Debridement
medicine.drug_class
Acute phase proteins
Aggressive Periodontitis/blood/drug therapy/surgery
Cytokines/blood
Serum Amyloid P-Component/analysis
03 medical and health sciences
Double-Blind Method
Internal medicine
Metronidazole
medicine
Humans
Protein Precursors
General Dentistry
Aged
Periodontitis
Haptoglobins/analysis
Haptoglobins
business.industry
Protein Precursors/blood
Ferritins/blood
Periodontal therapy
Amoxicillin
030206 dentistry
medicine.disease
Surgery
Clinical trial
Anti-Bacterial Agents/therapeutic use
Interleukin 1 Receptor Antagonist Protein
Metronidazole/therapeutic use
Interleukin 1 Receptor Antagonist Protein/blood
Chronic Periodontitis
Ferritins
Periodontal Debridement/methods
business
Biomarkers/blood
Biomarkers
Acute-Phase Proteins
Follow-Up Studies
Subjects
Details
- ISSN :
- 15440591 and 00220345
- Volume :
- 95
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of dental research
- Accession number :
- edsair.doi.dedup.....fbc1ffd03b6c06785cd466f0cc2c7539